Table 4 Single-factor analysis of PFS and OS in the two groups of patients
n | PFS (months) 95% CI | P | OS (months) 95% CI | P | |
|---|---|---|---|---|---|
Ages (years) | 0.676 | 0.858 | |||
≥ 50 | 45 | 3.60(3.01–4.19) | 8.70 (4.42–12.98) | ||
< 50 | 63 | 4.00(3.42–4.58) | 10.00 (8.52–11.48) | ||
Recurrent lesions | 0.034 | 0.009 | |||
In pelvic cavity | 27 | 6.3(2.48–11.51) | 15.8(12.53–19.07) | ||
Out of pelvis | 81 | 3.60(2.95–4.25) | 9.00(7.10–10.90) | ||
CA125 level | 0.001 | 0.038 | |||
Decline | 38 | 7.0(3.86–10.15) | 12.00(7.63–16.37) | ||
Poor decline | 70 | 3.0(1.91–4.09) | 9.30(5.10–13.51) | ||
Adverse reactions | 0.089 | 0.540 | |||
≥ 3 | 27 | 3.60(2.94–4.26) | 9.30(6.55–12.05) | ||
None or ≤ 2 | 81 | 4.20(2.43–5.97) | 10.60(7.95–13.25) | ||
FIGO Stage | 0.912 | 0.667 | |||
IIIC | 76 | 3.80(3.43–4.17) | 12.70(4.47–20.93) | ||
IV | 32 | 3.30(1.84–4.76) | 9.70(7.87–11.53) | ||
Treatment course | 0.000 | 0.000 | |||
≥ 3 cycles | 58 | 6.2(4.02–8.38) | 14.00(8.78–19.22) | ||
< 3 cycles | 50 | 2.2(1.87–2.53) | 5.10(2.87–7.33) | ||
Surgery again after recurrence | 0.046 | 0.065 | |||
Yes | 37 | 6.0(3.68–8.32) | 14.0(9.28–18.72) | ||
No | 71 | 3.6(2.69–4.51) | 9.00(7.15–10.85) | ||
Histology | 0.939 | 0.886 | |||
Serous | 82 | 3.80(3.41–4.06) | 10.50(8.74–12.26) | ||
Non-serous | 26 | 3.80(1.93–5.67) | 9.30(7.12–11.48) | ||
Ascites | 0.008 | 0.031 | |||
Yes | 38 | 2.2(1.41–2.98) | 6.10(2.32–9.88) | ||
No | 70 | 4.2(2.47–5.93) | 10.7(8.40–13.00) | ||
Basic illness | 0.163 | 0.729 | |||
Yes | 41 | 3.60(2.74–4.46) | 9.30(6.94–11.66) | ||
No | 67 | 4.00(3.46–4.54) | 10.70(7.75–13.65) |